New combo therapy targets Brain-Attacking antibodies in severe encephalitis
NCT ID NCT06867991
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two drugs—ofatumumab and daratumumab—can safely and effectively treat people with severe anti-NMDAR autoimmune encephalitis, a condition where the immune system attacks the brain. The drugs aim to eliminate the harmful immune cells producing the antibodies. The trial enrolls 200 participants aged 12 and older who have not responded well to standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 450000, China
-
The First People's Hospital of Changzhou
RECRUITINGChangzhou, Jiangsu, 213000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.